11th Annual European Congress: Preliminary Program
 
Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube

Program - Monday, 10 November 2008
7:00-8:00
Educational Symposium (Sponsored by UBC)
Risk-sharing Agreements: All Pain or Some Gain?
8:00-8:15
Exhibits & Poster Presentations Viewing Session II
8:15-9:45
Second Plenary Session
Improving Equity of Access to Pharmaceutical Therapies in Europe, Middle East & Africa

Despite improvements in indicators of health over the past few decades, health care inequities, specifically access to drugs, between and within countries in Eastern Europe, Middle East, and Africa have persisted. This plenary session will address equity of access to drugs in these regions and priorities for research.

John Yfantopoulos PhD Moderator:
John Yfantopoulos PhD
Professor of Health Economics, University of Athens and President of the National Centre for Social Research, Athens, Greece
HEALTH CARE EQUITY ISSUES IN RUSSIA
   
Speakers:  
Professor Pavel Vorobyev MD, PhD Professor Pavel Vorobyev MD, PhD
Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow, Russia and President ISPOR Russia Chapter;
Oleg Borisenko MD Oleg Borisenko MD
Executive Director, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
HEALTH CARE EQUITY ISSUES IN MIDDLE EAST
   
Speaker:  
Dr. Ibrahim Al-Abbadi PhD, MBA Dr. Ibrahim Al-Abbadi PhD, MBA
Assistant Professor, University of Jordan, Faculty of Pharmacy, Amman, Jordan and President ISPOR Jordan Chapter
HEALTH CARE EQUITY ISSUES IN AFRICA
   
Speaker:  
Tienie Stander MBChB, MBA Tienie Stander MBChB, MBA
Honorary Professor, North West University, School of Pharmacy, Johannesburg, South Africa and President, ISPOR South Africa Chapter

9:45-10:15
Break, Exhibits & Poster Presentations Viewing – Session II
10:15-11:15
Issue Panels – Session I

ECONOMIC OUTCOMES RESEARCH ISSUES
IP1: DISCRETE EVENT SIMULATION OR MARKOV MODEL: WAR OF THE WORLDS OR EXPANDING THE GALAXY?
Moderator: Bengt Jönsson PhD, Professor of Health Economics, Stockholm School of Economics, Stockholm, Sweden
Panelist(s): J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President Health Economics, United BioSource Corporation, Lexington, MA, USA; Mark J. Sculpher PhD, Professor, University of York, York, UK

PATIENT-REPORTED OUTCOMES RESEARCH ISSUES
IP2: PATIENT-REPORTED OUTCOME (PRO) AND UTILITY DATA IN MARKET ACCESS DECISION-MAKING
Moderator: Anne Heyes MBA, Research Manager, Mapi Values, Cheshire, UK
Panelist(s): Jan J. Busschbach PhD, Senior Research Associate, Erasmus Medical Center, Rotterdam, The Netherlands; Chloë Brown PhD, Director, Mapi Values, Lyon, France

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP3: ADVANCING METHODS IN PERSONALIZED MEDICINE FOR CLINICAL DECISION-MAKING (Speakers at this panel were invited)
Moderator: Uwe Siebert MD, MPH, MSc, ScD, Professor/Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment at the University of Health Sciences, Medical Informatics and Technology, i.T, Austria
Panelists: M.J. Finley Austin PhD, Director, US External Science Policy, F. Hoffmann-La Roche Ltd., Basel, Switzerland; David L. Veenstra PharmD, PhD, Associate Professor, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA; Adrian Towse MA, MPhil, Director, Office Health Economics, London, UK

IP4: ISPOR GREECE CHAPTER PANEL: IS ECONOMIC EVALUATION IN THE GREEK HEALTH CARE CONTEXT A FEASIBLE TARGET OR AN INTANGIBLE DREAM?
Moderator: Mary Geitona PhD, Assistant Professor, University of Thessaly, Volos, Greece
Panelist(s): Sotiria Papanicolaou MSc, MBA, Health Economics Manager, Janssen-Cilag Pharmaceutical SACI, Athens, Greece; Vassilis Kontozamanis MSc, MBA, President, National Organization for Medicines, Athens, Greece; Nikolaos Maniadakis PhD, Assistant Professor, University of Piraeus, Piraeus, Greece 

IP5: WHAT IS THE ROLE OF HTA IN INTERNATIONAL DECISION-MAKING?
Moderator: Mark JC Nuijten MD, PhD, MBA, Physician and Health Economist, Erasmus University, Rotterdam, The Netherlands
Panelist(s): Wolfgang Greiner PhD, Professor for Health Economics and Health Care Management, University of Bielefeld, Bielefeld, North Rhine-West, Germany; Peter J. Neumann ScD, Professor, Tufts-New England Medical Center, Boston, MA, USA; Gerry Oster PhD, Vice-President, PAI, Brookline, MA, USA

11:15 11:30
Break, Exhibits & Poster Presentations Viewing – Session II
11:30-12:30
Podium Presentations – Session III
Health Care Decisions Using Outcomes Research Case Studies
CASE1 IMPLEMENTATION OF TRANSPARENT PROCESS OF DRUG REIMBURSEMENT DECISIONS IN POLAND
Zagorska A1, Krol Z1, Lipska I1, Falek A2, Sauvage P3, Barna A3, van Ormondt T4
1Agency for Health Technology Assessment, Warszawa, Poland, 2Ministry of Health, Warszawa, Poland, 3Ministry of Health, Paris, France, 4Law Online - EU expert, Leiden, The Netherlands
CASE2 DO TECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?: FINDINGS FROM, AND IMPLICATIONS OF, ONTARIO'S EVIDENCE-BASED HTA PROCESS
Goeree RA
Ontario Health Technology Advisory Committee (OHTAC), Hamilton, ON, Canada
CASE3 A CHANGE IN REIMBURSEMENT STRATEGY IN ICELAND: AIMING AT VALUE-BASED PRICING.
Hauksdottir R1, Björnsdottir I2, Kanavos P3
1Icelandic Medicine Pricing and Reimbursement Committee, Reykjavik, Iceland, 2Bifröst University, Borgarnes, Iceland, 3London School of Economics, London, UK
   
Cancer Economic Evaluations I 
CN1  PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: BUDGET IMPACT ANALYSIS OF PACLITAXEL PROTEIN-BOUND AT A MAJOR CANCER CENTER 
Miller LA, Lau J, Lal LS, Arbuckle R
University of Texas - MD Anderson Cancer Center, Houston, TX, USA 
CN2  ESTIMATING TARGET POPULATION SIZE FOR BUDGET IMPACT: AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASIS IN THE UK. 
Gauthier A1, Gennari A2, Martin M3, Maetzel A4
1i3 Innovus, Uxbridge, UK, 2National Cancer Research Institute, Genoa, Italy, 3i3 Innovus, Uxbridge, Middlesex, UK, 4Amgen (Europe) GmbH / University of Toronto, Zug, Switzerland 
CN3  COST OF INITIAL PROSTATE CANCER TREATMENT FOLLOWING DIAGNOSIS PER PATIENT BY STAGE: ESTIMATES FROM THE UK, FRANCE, GERMANY, ITALY AND SPAIN 
Benedict Á1, Black L2, Stokes ME3
1United BioSource Corporation, Budapest, Hungary, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3United BioSource Corporation, Dorval, QC, Canada 
CN4  YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY COSTS DUE TO CANCER MORTALITY AND FOR SPECIFIC CANCER SITES WHERE HPV MAY BE A RISK FACTOR FOR CARCINOGENESIS—UNITED STATES, 2003 
Ekwueme DU1, Chesson HW1, Zhang KB2, Balamurugan A3
1U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Macro International Inc, Bethesda, MD, USA, 3Arkansas Department of Health, Little Rock, AR, USA 
 
Infectious Disease Economic Evaluations 
IN1  COST EFFECTIVENESS ANALYSIS OF REYATAZ® VERSUS KALETRA® IN THE TREATMENT OF NAÏVE HIV PATIENTS IN ITALY 
Thuresson PO1, Heeg B1, Neubauer AS2, Intorcia M3, Van Hout BA1
1Pharmerit BV, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Munich, Germany, 3Bristol-Myers Squibb, Rome, Italy 
IN2  MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM 
Lescrauwaet B1, Nevens F2, Zammit D1, Yuan Y3, Hay JW4
1Bristol-Myers Squibb, Braine l'Alleud, Belgium, 2UZ Gasthuisberg KULeuven, Leuven, Belgium, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4University of Southern California, Los Angeles, CA, USA 
IN3  PHARMACOECONOMIC ANALYSIS OF ITRACONAZOLE ORAL SOLUTION IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKEY 
Kanbur B1, Azap A2, Arat M2, Sarioz F1, Tatar F1
1Janssen-Cilag, Istanbul, Turkey, 2Ankara University, Ankara, Turkey 
PIN44 IMPACT OF ETRAVIRINE ON HOSPITALIZATIONS AND HOSPITAL RELATED COSTS IN BELGIUM: 48-WEEK FINDINGS FROM POOLED DUET TRIALS
  Martin SC1, Spaepen E2, Corbett CJ3, De Smedt G3
  1Johnson & Johnson Pharmaceutical Services, LLC, Mechelen, Belgium, 2SBD Analytics, Bekkevoort, Belgium, 3Tibotec-Virco, Mechelen, Belgium
 
Muscular-Skeletal Disease Evaluations 
MS1  PREVALENCE OF FIBROMYALGIA IN EUROPE- A TIP OF THE ICEBERG.RESULTS FROM A LARGE-SCALE SURVEY 
Le Lay K1, Branco J2, Bannwarth B3, Matucci Cerinic M4, Blotman F5, Spaeth M6, Carbonell JA7, Failde I8, Saraiva F9, Nacci F4, Thomas E5, Boussetta S1, Taieb C1
1Pierre Fabre, Boulogne, France, 2CHLO, EPE/Hospital Egas Moniz, Lisboa, Portugal, 3Université V. Segalen, Bordeaux, France, 4Univ. Firenze, Florence, Italy, 5Lapeyronie Hospital, Montpellier, France, 6Unit Rheumatology, Munich, Germany, 7Hospital de la Esperanz, Barcelona, Spain, 8Universidad de Cadiz, Cadix, Spain, 9Hospital Santa Maria, EPE, Lisboa, Portugal 
MS2  LINGUISTIC VALIDATION OF SIX QUALITY OF LIFE QUESTIONNAIRES FOR FIBROMYALGIA PATIENTS IN TWELVE LANGUAGES 
Nadjar A1, Le Gal M1, Mainguy Y2, Le Lay K3, Taieb C3
1MAPI Research Institute, Lyon, France, 2Pierre Fabre Laboratories, Labège, France, 3Pierre Fabre, Boulogne, France 
MS3  POPULATION HEALTH-STATE UTILITIES FOR FIBROMYALGIA IN THE UK 
Hauber AB1, McCrink L2, Beard S2, Garcia-Cebrian A3, Maas G4, Das Gupta R5, Le TK6
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK, 3Eli Lilly and Company Limited, Basingstoke, UK, 4Boehringer Ingelheim GmbH, Ingelheim, Germany, 5Boehringer Ingelheim, Bracknell, Berkshire, UK, 6Eli Lilly and Company, Indianapolis, IN, USA 
MS4  GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY 
Braun J1, Inman RD2, van der Heijde D3, Mack M4, Parasuraman S5, Buchanan J5, Hsu B4, Beutler A4, Han C5, Deodhar A6
1Rheumazentrum Ruhrgebiet, Herne, Germany, 2University of Toronto, Toronto, ON, Canada, 3Leiden University Medical Center, Leiden, The Netherlands, 4Centocor Research and Development, Inc, Malvern, PA, USA, 5Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 6Oregon Health and Science University, Portland, OR, USA 
   
Quality of Life/Prefence-Based Measures III 
QL9  DEVELOPMENT AND VALIDATION OF AN ELETRONIC VERSION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) 
Tiplady B1, Carrington R2, Battersby C3, Wilson K4, Cummings G5, Lyle D5, Ralston S4
1PRO Consulting, London, UK, 2AstraZeneca R & D Charnwood, Loughborough, UK, 3AstraZeneca R & D Alderley Park, Macclesfield, UK, 4University of Edinburgh, Edinburgh, UK, 5Wellcome Trust Clinical Research Facility, Edinburgh, UK 
QL10  DEVELOPMENT AND VALIDATION OF THE SATISFACTION WITH MEDICATION QUESTIONNAIRE (SAT-Q) IN PATIENTS WITH CHRONIC DISEASE 
Cuervo J1, Rebollo P1, Zardain PC1, Tranche S2, Barreda MJ2, Prieto MA2, Sánchez-Baragaño M2
1BAP Health Outcomes Research, Oviedo, Spain, 2SESPA, Oviedo, Spain 
QL11  FATIGUE REDUCTION AND PHYSICAL FUNCTION IMPROVEMENTS ASSOCIATED WITH INCREASED PRODUCTIVITY AT WORK AND AT HOME IN RHEUMATOID ARTHRITIS PATIENTS 
Hazes M1, Purcaru O2, Coteur G3, Mease P4
1Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands, 2UCB, Braine l'Alleud, Belgium, 3UCB, Braine L'Alleud, Belgium, 4Seattle Rheumatology Associates, Seattle, WA, USA 
QL12  FRENCH NORMATIVE REFERENCE DATA FOR THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA) QUESTIONNAIRE 
Chachuat A1, Koltowska-Haggstrom M2, Gilet H3, Auziere S4, Guillaume X4, Arnould B3, Viala M3
1Pfizer, Paris, France, 2KIMS Medical Outcomes, Pfizer Endocrine Care, Sollentuna, Sweden, 3Mapi Values, Lyon, France, 4TNS-Healthcare, Montrouge, France 
12:30-14:00
Lunch, Exhibits & Poster Presentations Viewing – Session II
12:45-13:45
Educational Symposium (Sponsored by IMS Health)
Finding Synergies between Pricing & Reimbursement and Health Economics and Outcomes Research
14:00-15:00
Podium Presentations – Session IV
Arthritis Outcomes Measurement 
AR1  PRODUCTIVITY LOSS AT WORK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS 
Braakman-Jansen LM1, Taal E1, Kuper I2, van de Laar MA2
1University of Twente, Enschede, The Netherlands, 2Medisch Spectrum Twente Hospital, Enschede, The Netherlands 
AR2  A COST EFFECTIVENESS ANALYSIS OF INFLIXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN SWEDEN, BASED ON DATA FROM THE STURE REGISTRY 
Lekander I1, Borgström F1, Carli C2, Svarvar P3, Ljung T3, van Vollenhoven R2
1i3 Innovus, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Schering-Plough AB, Stockholm, Sweden 
AR3  TO INVESTIGATE THE BENEFIT OF ANTI-TNF THERAPY ION PHYSICAL AND MENTAL FUNCTIONING VIA THE SHORT FORM-36 QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS 
Adams R1, Ng CT2, Gibbs A3, Bresnihan B4, Veale D5, Tilson L1, FitzGerald O5, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2St.Vincents University, Dublin, Ireland, 3Galway Clinic, Galway, Ireland, 4St Vincents University Hospital, Dublin, Ireland, 5St.Vincents University Hospital, Dublin, Ireland 
AR4  MEASUREMENT AND RATES OF ADHERENCE TO BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS 
Kim MM, Pahira J, Doshi JA
University of Pennsylvania, Philadelphia, PA, USA 
 
Cancer Economic Evaluations II
CN5  EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UK 
Gyldmark M1, Gatzemeier U2, Nicolson M3, Latimer N4, Walzer S5
1F Hoffmann La Roche, Basel, Switzerland, 2Hospital Grosshansdorf, Grosshansdorf, Germany, 3Royal Infirmary Aberdeen, Aberdeen, UK, 4Roche Products Ltd, Welwyn Garden City, UK, 5F. Hoffmann - La Roche Ltd, Basel, Switzerland 
CN6  COST-EFFECTIVENESS OF A HUMAN PAPILLOMAVIRUS VACCINE IN REDUCING THE RISK OF CERVICAL CANCER IN IRELAND USING A TRANSMISSION DYNAMIC MODEL 
Usher C1, Tilson L1, Olsen J2, Rudbeck Jepsen M3, Walsh C4, Barry M1
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2University of Southern Denmark, Odense, Denmark, 3Statens Serum Institut, DK-2300 Copenhagen S, Denmark, 4Trinity College Dublin, Dublin, Ireland 
CN7  MODELING THE COST-EFFECTIVENESS OF A NEW AND EXPENSIVE TREATMENT MODALITY IN LUNG CANCER: THE CASE OF PARTICLE THERAPY 
Grutters JP1, Pijls-Johannesma M1, De Ruysscher D1, Dekker AL1, Peeters A1, Severens JL2, Lambin P1, Joore MA2
1Maastro Clinic, Maastricht, The Netherlands, 2University Hospital Maastricht, Maastricht, The Netherlands 
CN8  AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE 
Nagy B1, Kutikova L2, Stastny M2, Vasile K3, Zsolnai Nagy I4, Mayer J5
1Healthware Consulting Ltd, Budapest, Hungary, 2Bristol-Myers Squibb, Prague, Czech Republic, 3Bristol-Myers Squibb, Bucharest, Romania, 4Bristol-Myers Squibb, Budapest, Hungary, 5University Hospital Brno, Brno, Czech Republic 
 
Diabetes Economic Impact
DB1  ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO IN TYPE 1 DIABETES IN THE UK: A COST-EFFECTIVENESS ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSIS 
Smith HT1, Valentine WJ2, Boye KS3, Kalsekar A3, Pratoomsoot C2
1Eli Lilly and Company, Surrey, UK, 2IMS Health, Basel, Switzerland, 3Eli Lilly and Company, Indianapolis, IN, USA 
PDB36  COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA 
Minshall ME1, Swan T2, Slusarek B2, Ikramuddin S2
1IMS Health, Noblesville, IN, USA, 2University of Minnesota, Minneapolis, MN, USA 
DB3  HEALTH CARE RESOURCE UTILIZATION AND COSTS IN INSULIN-DEPENDENT PATIENTS WITH TYPE 2 DIABETES UNDER REAL WORLD CONDITIONS IN GERMANY: LIVE-SPP STUDY 
Schöffski O1, Dippel FW2, Breitscheidel L3, Benter U3, Müller M4, Volk M4
1Universität Erlangen-Nürnberg, Nürnberg, Germany, 2Sanofi-Aventis Germany GmbH, Berlin, Germany, 3Kendle GmbH, Munich, Germany, 4axaris software&systeme GmbH, Ulm, Germany 
DB4  COST OF MANAGING SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES 
Hammer M1, Lammert M2, Frier BM3
1Novo Nordisk A/S, Bagsværd, Denmark, 2Novo Nordisk Scandinavia AB, Copenhagen, Denmark, 3Royal Infirmary of Edinburgh, Edinburgh, UK 
 
Health Policy Issues and Implications 
HP1  ANALYSIS OF THE ORPHAN DRUG DESIGNATIONS AND APPROVALS GRANTED BY THE EMEA AND THE USA FDA BETWEEN 2000 AND 2007 
Seoane-Vazquez E1, Rodriguez-Monguio R2
1The Ohio State University, Columbus, OH, USA, 2University of Massachusetts, Amherst, MA, USA 
HP2  NEONATAL INTENSIVE CARE UNITS (NICUS) IN GREECE: FACTORS AFFECTING THE LENGTH OF STAY (LOS) OF THE NEONATES AND THE DRIVERS OF COST 
Hatzikou M1, Alexopoulos E2, Chatzistamatiou Z3, Geitona M1
1University of Thessaly, Volos, Greece, 2University of Patras, RIO, Greece, 3Alexandra General Hospital, Neo Faliro, Greece 
HP3  TREATMENTS PATTERNS, RESOURCE USE AND RELATED HEALTH CARE COSTS IN DEPRESSED PATIENTS WITH CO-MORBID ANXIETY IN A LARGE US CLAIMS DATABASE 
Guelfucci F1, François C2, Milea D2, Saragoussi D2, Toumi M3
1Altipharm, Paris, France, 2Lundbeck SAS, Paris, France, 3Université Lyon I, Villeurbanne, France 
HP4  THE IMPACT OF A MEDICAID EXPANSION TO INCLUDE POPULATION WITH LOW INCOME ON THE PREVENTABLE HOSPITALIZATIONS 
Shin H, Kim S
Health Insurance Review & Assessment Service, Seoul, South Korea 
   
Outcomes Research Issues
OR1  EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES USING PROBIT REGRESSION ANALYSIS 
Conlon J1, Xu X2, Zlateva G3, Knight T2
1Covance, Inc, Princeton, NJ, USA, 2Covance Market Access Services Inc, Gaithersburg, MD, USA, 3Pfizer, Inc, New York, NY, USA 
OR2  INCORPORATING DIFFUSION OF NEW MEDICINES IN A BUDGET IMPACT ANALYSIS 
ter Borg J1, Al MJ2
1IMS Health, Den Haag, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands 
OR3  ADJUSTING ICERS FOR FUTURE UNRELATED MEDICAL COSTS: DEVELOPMENT AND APPLICATION OF A TOOLKIT 
De Wit GA, Tariq L, Wong A, Polder JJ, van Baal P
National Institute of Public Health and the Environment, Bilthoven, The Netherlands 
OR4  UTILITIES SHOULD NOT BE MULTIPLIED: EVIDENCE FROM THE PREFERENCE-BASED SCORES IN THE UNITED STATES 
Fu AZ, Kattan MW
Cleveland Clinic, Cleveland, OH, USA
15:00-15:15
Break, Exhibits & Poster Presentations Viewing – Session II
15:15-16:15
Workshops – Session I

CLINICAL OUTCOMES RESEARCH
W1: TIME-DEPENDENT SURVIVAL MODELS IN HEALTH OUTCOMES STUDIES: POTENTIAL PITFALLS AND HOW TO AVOID THEM
Discussion Leaders: Victor A. Kiri MSc, PhD, CStat, Professor & Director of Pharmacoepidemiology, PAREXEL International, Uxbridge, London, UK; Maurille Feudjo-Tepie MSc, PhD, Medical Statistician, GlaxoSmithKline R&D, London, UK; David Todem MSPH, PhD, Assistant Professor, Michigan State University, East Lansing, MI, USA; Gilbert MacKenzie MSc, PhD, CStat, Professor & Director of Centre of Biostatistics, University of Limerick, Limerick, Ireland

ECONOMIC OUTCOMES RESEARCH
W2: CHALLENGES OF DEVELOPING ECONOMIC EVALUATIONS FOR ORPHAN DRUGS

Discussion Leaders: Mike F. Drummond PhD, Professor, University of York, York, Heslington, UK; Aline Gauthier MSc, Lead Analyst, i3 Innovus Research Inc, Uxbridge, UK; Tsveta Milanova MSc, Health Outcomes Manager, GlaxoSmithKline R&D, Greenford, UK

W3: THRESHOLD PRICING ANALYSIS: AN ECONOMISTS' CONTRIBUTION TO PHARMACEUTICAL PRICING
Discussion Leaders: Deirdre Mladsi BA, Global Head, RTI Health Solutions, Research Triangle Park, NC, USA; Hediyyih Narula BS, Health Outcomes Scientist, RTI Health Solutions, Research Triangle Park, NC, USA; W. Neil Palmer BA, Vice President, RTI Health Solutions, Ottawa, ON, Canada; David W. Miller PhD, President, Miller Pharma Consulting, London, UK

PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH
W4: HEALTH-BELIEFS – WHAT ROLE DO THEY PLAY IN OUTCOMES RESEARCH?
Discussion Leaders: Matthew D. Reaney MSc, PGDip, Senior Scientist, Health Psychology, AHP Research, Uxbridge, UK; Aysha Malik-Aslam BSc, Scientist, AHP Research, Uxbridge, UK; Colin Martin RN, BSc, PhD, YC, Chair in Mental Health, University of the West of Scotland, Ayr, Scotland, UK; Jane Speight MSc, PhD, Director, AHP Research, Uxbridge, UK  

W5: PATIENT-REPORTED OUTCOME - VALUE BEYOND THE LABEL CLAIM
Discussion Leaders: Ari Gnanasakthy MSc, Director, Novartis Pharmaceuticals, East Hanover, NJ, USA; Lynda C. Doward MRes, Associate Director of Research, Galen Research, Manchester, UK; Mary G. Baker MBE, President, European Federation of Neurological Associations, Firenze, Italy  

USE OF REAL WORLD DATA
W6: THE ROLE OF OBSERVATIONAL STUDIES IN DEMONSTRATING PRODUCT VALUE AND BENCHMARKING PRODUCT SAFETY
Discussion Leaders: Thomas Goss PharmD, Vice President, Boston Healthcare Associates, Washington, DC, USA; Gergana Zlateva PhD, Director, Global Outcomes Research, Pfizer Inc, New York, NY, USA  

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W7: WHY IS IT SO DIFFICULT TO IMPLEMENT COST CONTAINMENT REFORMS AND MAKE VALUE-BASED DECISIONS IN THE GREEK HEALTH CARE SYSTEM?
Discussion Leaders: Antonis Karokis MSc, Government and Public Affairs Manager, Wyeth, Athens, Greece; John Yfantopoulos PhD, Professor of Health Economics and Social Policy, University of Athens, Ekali, Greece; Nikolaos Maniadakis PhD, Assistant Professor, University of Piraeus, Piraeus, Greece; Kyriakos Souliotis, PhD, Lecturer, University of Peloponnese, Maroussi, Greece

16:15-16:30
Break, Exhibits & Poster Presentations Viewing – Session II
16:30-17:30
Workshops – Session II

ECONOMIC OUTCOMES RESEARCH
W9: TRIVIAL OR IMPORTANT? THE NEEDS, BENEFITS AND IMPLICATIONS OF VARIABILITY

Discussion Leaders: Denis Getsios BA, Graduate Student, College of Pharmacy, Dalhousie University, Halifax, NS, Canada; Kristen Migliaccio-Walle BS, Director & Research Scientist, Health Economics, United BioSource Corporation, Concord, MA, USA; Duygu Bozkaya MSc, MBA, Researcher, United BioSource Corporation, Concord, MA, USA

W10: GUIDELINES FOR APPROPRIATE SELECTION OF MODELING APPROACH IN PHARMACOECONOMIC EVALUATION
David Thompson PhD, Vice President, i3 Innovus Research, Inc, Medford, MA, USA; Andreas Maetzel MD, MSc, PhD, Assoc. Director / Assistant Professor, Amgen (Europe) GmbH / University of Toronto, Health Economics & Reimbursement, Zug, Switzerland; Monique Martin MSc, MBA, Vice-President UK Operations, i3 Innovus Research Inc, Uxbridge, UK; Peter Lindgren PhD, Director, i3 Innovus Research Inc, Stockholm, Sweden

PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH
W11: MISSING DATA – IMPLICATIONS FOR OUTCOMES RESEARCH AND STRATEGIES TO MAXIMISE DATA INTEGRITY
Discussion Leaders: Colin Martin RN, BSc, PhD, YC, Chair in Mental Health, University of the West of Scotland, Ayr, Scotland, UK; Matthew D. Reaney MSc, PGDip, Senior Scientist, Health Psychology, AHP Research, Uxbridge, UK; Jane Speight MSc, PhD, Director, AHP Research, Uxbridge, UK

W12: RAISING THE VALUE OF DIRECT UTILITY MEASUREMENT APPROACHES FOR PHARMACEUTICAL MARKET ACCESS DECISION MAKING: IS IT POSSIBLE?
Discussion Leaders: Keith H. Tolley MPhil, Director, Tolley Health Economics Limited, Buxton, Derbyshire, UK; Jan J. Busschbach PhD, Senior Research Associate, Erasmus Medical Center, Rotterdam, The Netherlands; Jane Scott PhD, Research Director, Mapi Values, Macclesfield, Cheshire, UK

USE OF REAL WORLD DATA
W13: HEALTH TECHNOLOGY ASSESSMENT RESEARCH IN EUROPE: GATHERING THE DATA
Discussion Leaders: Carl V. Asche PhD, Research Associate Professor, University of Utah College of Pharmacy, Salt Lake City, UT, USA; William C. Maier MPH, PhD, Scientific Advisor, MAPI Research Trust, Lyon, France

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W14: DECISION CRITERIA BY HEALTH INSURERS: WHAT DO THEY WANT FROM US?
Discussion Leaders: Eline Kogels MSc, Consultant, Kogels Consultancy Network, Amsterdam, The Netherlands; Mark JC Nuijten MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands

17:30-18:30
Poster Author Discussion Hour – Session II
ISPOR Forums
Equity and Access to Pharmaceutical Therapies in Russia (presented in Russian with English handouts and slides)
Presented by: The ISPOR-Russia Chapter
The ISPOR-Russia chapter will present information on access and equity to medical care challenges facing the Russian population. The forum will cover problems with access to therapies, medicines and general health care that currently exist in Russia. The discussion will extend to possible solutions, role of patients, and professional organizations in influencing and monitoring the situation and collaborating with the Russian government to improve conditions.

Moderator: Pavel Vorobiev MD, PhD, Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow, Russia and President ISPOR Russia Chapter;
Speakers: Pavel Vorobiev MD, PhD, Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow, Russia and President ISPOR Russia Chapter; Oleg Borisenko MD, Executive Director, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

17:30-19:30
Exhibitors’ Wine & Cheese Reception & Poster Presentations
19:30-TBD
ISPOR Social Event

11th Annual European Congress Main Page

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.